0.5-1 mg/day at intervals ≥24 hr to recommended dosage of 2.5 mg/day; dosage range: 0.5-6 mg/day (dosages >2.5 mg/day have not been proved more effective and are associated with increased incidence of adverse effects) If persistent somnolence occurs, daily dose may be divided q12hr Autism Irritability associated with autistic disorder in children aged 5-16 years <5 years: Safety and efficacy not established 5-16 years (<20 kg): 0.25 mg/day PO initially; may be increased after ≥4 days to recommended dosage of 0.5 mg/day 5-16 years (≥20 kg): 0.5 mg/day PO initially; may be increased after ≥4 days to recommended dosage of 1 mg/day Insufficient response to recommended dosage If response to recommended dosage insufficient, dosage may be adjusted as follows after minimum of 14 days and at least every 2 weeks thereafter <20 kg: Adjusted in increments of 0.25 mg/day; not to exceed 1 mg/day ≥20 kg: Adjusted in increments of 0.5 mg/day; not to exceed 2.5 mg/day Not approved for dementia-related psychosis, because of increased risk of cardiovascular or infectious related deaths (see Black Box Warnings) Risk of orthostatic hypotension higher in elderly; monitoring of renal function and orthostatic blood pressure may be necessary; for titrating to target dose, twice-daily regimen should be used and dosage maintained for 2-3 days before change is made to once-daily dose regimen Schizophrenia, Bipolar Mania Use lower initial dose, and adjust more gradually PO: 0.5 mg q12hr; may be increased in increments ≤0.5 mg q12hr; increases to dosages >1.5 mg q12hr should occur at intervals ≥1 week IM: 12.5-25 mg injected into deltoid or gluteal muscle every 2 weeks; dosage should not be adjusted more frequently than every 4 weeks Recommended to establish tolerability of PO risperidone before initiating treatment with IM risperidone Psychosis, Agitation Related to Alzheimer Dementia (Off-label) 0.25-1 mg/day PO initially; may be increased gradually as tolerated; not to exceed 1.5-2 mg/dayInteraction CheckerEnter a drug name and risperidoneNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)amisulprideamisulpride, risperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.Serious - Use Alternative (74)adagrasibadagrasib, risperidone. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.amiodaroneamiodarone will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of amiodarone and risperidone is not recommended due to the potential for inducing life-threatening arrhythmias. If concurrent use cannot be avoided, cautious dosing and telemetric monitoring is advised.amiodarone and risperidone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideamisulpride and risperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.anagrelideanagrelide and risperidone both increase QTc interval. Avoid or Use Alternate Drug.apomorphinerisperidone decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.artemetherartemether and risperidone both increase QTc interval. Avoid or Use Alternate Drug.asenapineasenapine and risperidone both increase QTc interval. Avoid or Use Alternate Drug.asenapine transdermalasenapine transdermal and risperidone both increase QTc interval. Avoid or Use Alternate Drug.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, risperidone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.bromocriptinerisperidone decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.buprenorphinebuprenorphine and risperidone both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and risperidone both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and risperidone both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermalbuprenorphine transdermal and risperidone both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine, long-acting injectionbuprenorphine, long-acting injection and risperidone both increase QTc interval. Avoid or Use Alternate Drug.cabergolinerisperidone decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.calcium/magnesium/potassium/sodium oxybatesrisperidone, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.ceritinibceritinib and risperidone both increase QTc interval. Avoid or Use Alternate Drug.citalopramcitalopram and risperidone both increase QTc interval. Avoid or Use Alternate Drug.dacomitinibdacomitinib will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. degarelixdegarelix and risperidone both increase QTc interval. Avoid or Use Alternate Drug.desfluranedesflurane and risperidone both increase QTc interval. Avoid or Use Alternate Drug.disopyramidedisopyramide and risperidone both increase QTc interval. Avoid or Use Alternate Drug.dopaminerisperidone decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.efavirenzefavirenz and risperidone both increase QTc interval. Avoid or Use Alternate Drug.encorafenibencorafenib and risperidone both increase QTc interval. Avoid or Use Alternate Drug.entrectinibrisperidone and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.erdafitiniberdafitinib will increase the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If coadministration unavoidable, separate administration by at least 6 hr before or after administration of P-gp substrates with narrow therapeutic index.fexinidazolefexinidazole and risperidone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.fluoxetinefluoxetine will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.givosirangivosiran will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glasdegibrisperidone and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.hydrocodonehydrocodone, risperidone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.hydroxychloroquine sulfatehydroxychloroquine sulfate and risperidone both increase QTc interval. Avoid or Use Alternate Drug.ibutilideibutilide and risperidone both increase QTc interval. Avoid or Use Alternate Drug.indapamideindapamide and risperidone both increase QTc interval. Avoid or Use Alternate Drug.isofluraneisoflurane and risperidone both increase QTc interval. Avoid or Use Alternate Drug.ivosidenibivosidenib and risperidone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.lasmiditanlasmiditan increases levels of risperidone by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.lefamulinlefamulin and risperidone both increase QTc interval. Avoid or Use Alternate Drug.levodoparisperidone decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.levodopa inhaledrisperidone decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Atypical (2nd generation) antipsychotics inhibit dopamine D2 receptors in varying degrees (clozapine and quetiapine are lower risk). .lisuriderisperidone decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.lonafarnibrisperidone will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.macimorelinmacimorelin and risperidone both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.mefloquinemefloquine increases toxicity of risperidone by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.methyldoparisperidone decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.metoclopramide intranasalrisperidone, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.risperidone increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome.mobocertinibmobocertinib and risperidone both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.olopatadine intranasalrisperidone and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. ondansetronondansetron and risperidone both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.pentamidinepentamidine and risperidone both increase QTc interval. Avoid or Use Alternate Drug.pimozidepimozide and risperidone both increase QTc interval. Avoid or Use Alternate Drug.pitolisantrisperidone and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.pramipexolerisperidone decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.procainamideprocainamide and risperidone both increase QTc interval. Avoid or Use Alternate Drug.propafenonepropafenone will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of propafenone and risperidone is not recommended due to the potential for inducing life-threatening arrhythmias. If concurrent use cannot be avoided, cautious dosing and telemetric monitoring is advised.quinidinequinidine will increase the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.quinidine and risperidone both increase QTc interval. Avoid or Use Alternate Drug.ribociclibribociclib increases toxicity of risperidone by QTc interval. Avoid or Use Alternate Drug.ropinirolerisperidone decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamiderisperidone decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.selinexorselinexor, risperidone. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sevofluranesevoflurane and risperidone both increase QTc interval. Avoid or Use Alternate Drug.siponimodsiponimod and risperidone both increase QTc interval. Avoid or Use Alternate Drug.sodium oxybaterisperidone, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sotalolrisperidone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.sotorasibsotorasib will decrease the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications.sufentanil SLsufentanil SL, risperidone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tepotinibtepotinib will increase the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling.tetrabenazinetetrabenazine and risperidone both increase QTc interval. Avoid or Use Alternate Drug.umeclidinium bromide/vilanterol inhaledrisperidone increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vandetanibrisperidone, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs